For decades, the nerve damage suffered by colorectal cancer patients has been laid at the feet of chemotherapy — a reasonable assumption, but perhaps an incomplete one. Researchers at MD Anderson Cancer Center have found evidence that tumors themselves begin eroding peripheral nerves before treatment ever starts, driven by inflammation and disrupted fat metabolism that quietly degrade the protective sheaths nerves depend on. The discovery does not absolve chemotherapy, but it reframes the question: if the nervous system is already compromised when treatment begins, the suffering that follows m
Colorectal tumors damage nerves before chemotherapy begins, study finds
Colorectal cancer patients may experience undetected nerve damage and chronic pain or sensory dysfunction even after successful cancer treatment.
The damage would be latent, invisible, accumulating in the background.
Mark
So the cancer is damaging nerves before the chemotherapy even starts. How does that happen? What's the mechanism?
Mimi
The tumor creates an inflammatory environment—it's like a chronic wound that won't heal. That inflammation, combined with changes in how the body metabolizes fat, stresses the nerve cells and damages the myelin, which is the insulation around the nerves. It's not the chemotherapy drugs doing it; it's the tumor itself.
Mark
But if there's no pain, how would a patient or doctor know this is happening?
Mimi
That's the troubling part. The damage is silent. You might have thinning nerve fibers and problems with coordination, but no obvious pain or temperature sensitivity. It's like a slow leak in a pipe—by the time you notice water damage, the structural harm is already done.
Mark
Does that mean chemotherapy is making things worse on top of existing damage?
Mimi
That's the hypothesis the researchers are testing. If the tumor has already weakened the nerves, then chemotherapy drugs—which are known to be toxic to nerves—might hit an already-compromised system harder. It could explain why some patients develop severe, long-lasting neuropathy while others don't.
Mark
What did the anti-inflammatory drug do in the models?
Mimi
It helped with some of the early abnormalities, but it didn't prevent all the nerve injury. That tells us inflammation is part of the problem, but there's something else going on too—maybe the metabolic changes, maybe something about how the nerve cells are regulating calcium and transmitting signals.
Mark
So what happens next? How do we know if this matters in real patients?
Mimi
We need human studies. We need to look at nerve function in actual colorectal cancer patients before they start treatment, during treatment, and after. We need to see if the pattern holds across different cancer subtypes. Right now, this is preclinical evidence—it's compelling, but it's not yet proof that this is happening in people.
Der Puls
- Colorectal tumors silently damage peripheral nerves before chemotherapy begins, undermining the foundational assumption that treatment — not disease — is the primary cause of neuropathy in these patients.
- The damage is invisible in the worst possible way: nerve fibers thin, myelin sheaths deteriorate, and immune cells accumulate in sensory nerves, yet patients feel no pain and receive no warning.
- Tumor-driven inflammation and altered fat metabolism emerge as likely mechanisms, and while anti-inflammatory intervention reversed some early abnormalities in preclinical models, it could not prevent all nerve injury.
- The findings remain confined to preclinical models, leaving critical gaps — whether this pattern holds across cancer subtypes and in living patients has yet to be confirmed through human studies.
- If validated, the discovery could redefine survivorship care, suggesting that chronic pain and sensory dysfunction in cancer survivors may partly originate in the tumor itself, not solely in the drugs used to fight it.
For decades, the nerve damage suffered by colorectal cancer patients has been laid at the feet of chemotherapy — a reasonable assumption, but perhaps an incomplete one. Researchers at MD Anderson Cancer Center have found evidence that tumors themselves begin eroding peripheral nerves before treatment ever starts, driven by inflammation and disrupted fat metabolism that quietly degrade the protective sheaths nerves depend on. The discovery does not absolve chemotherapy, but it reframes the question: if the nervous system is already compromised when treatment begins, the suffering that follows may have roots deeper than the medicine. This shifts the moral and medical weight of survivorship, asking us to look at the cancer itself as an agent of long-term harm.
A research team at MD Anderson Cancer Center has challenged one of oncology's quiet assumptions: that peripheral neuropathy in colorectal cancer patients is primarily a consequence of chemotherapy. Their study, published in Nature Communications, found that tumors were already damaging peripheral nerves in preclinical models before any treatment began.
Led by Andrew Shepherd, an associate professor of translational neuroscience, the team observed that tumors degraded the myelin sheaths protecting peripheral nerve fibers and stressed the cells responsible for maintaining them. The damage was biologically significant but clinically silent — no pain, no obvious sensory changes, nothing to alert a patient or physician. Beneath that silence, small nerve fibers were thinning and coordination was subtly faltering.
The researchers identified tumor-driven inflammation and disrupted fat metabolism as likely drivers, with immune cells called macrophages accumulating in sensory nerves. An anti-inflammatory treatment improved some early abnormalities, but did not fully prevent nerve injury, suggesting inflammation is one thread in a more complex story.
The central implication is one of compounded vulnerability. If a patient's peripheral nervous system is already eroding when chemotherapy begins, those nerves may be far more susceptible to treatment-related damage — meaning the neuropathy survivors endure afterward may reflect both the medicine and the disease that preceded it.
Because the study was conducted in preclinical models, human validation remains essential. Researchers have not yet tracked nerve function in patients across the full arc of diagnosis and treatment, nor confirmed whether findings hold across colorectal cancer's varied subtypes. But the direction is clear: understanding when nerve damage truly begins could one day reshape how doctors protect quality of life — and how they assign responsibility for the suffering that outlasts the cancer itself.
A team of researchers at The University of Texas MD Anderson Cancer Center has upended a long-held assumption about nerve damage in colorectal cancer patients. For years, doctors have attributed peripheral neuropathy—the painful, sometimes debilitating damage to nerves outside the brain and spinal cord—almost entirely to chemotherapy drugs. But new work published in Nature Communications suggests the cancer itself is doing harm to these nerves long before treatment ever begins.
Andrew Shepherd, an associate professor of translational neuroscience who led the study, and his colleagues examined preclinical models of colorectal cancer and found something unexpected: tumors were already damaging the protective coating around peripheral nerves, disrupting the electrical signals those nerves depend on to function. The damage was subtle. Patients felt no obvious pain. They might not have known anything was wrong. Yet the nerve fibers were thinning, the protective myelin sheaths were deteriorating, and the cells responsible for maintaining those sheaths were showing signs of stress.
What makes this finding significant is what it suggests about vulnerability. If a tumor has already begun eroding a patient's peripheral nervous system before chemotherapy starts, those same nerves may be primed to suffer more severe or longer-lasting damage once treatment begins. The researchers found that tumor-driven inflammation and changes to fat metabolism were the likely culprits—both triggering stress in nerve cells and accumulating immune cells called macrophages in the sensory nerves. When the team treated models with an anti-inflammatory drug, some early abnormalities improved, but not all nerve injury was prevented, suggesting inflammation is part of the story but not the whole story.
The nerve damage observed in these models was remarkably quiet. Researchers saw loss of small nerve fibers in the skin and subtle problems with movement and coordination, yet no clear sensitivity changes to touch or temperature. This silence is precisely what makes the discovery troubling. A patient could harbor significant nerve damage and have no symptoms to alert them or their doctor. The damage would be latent, invisible, accumulating in the background.
Since the study was conducted in preclinical models rather than human tissue, important questions remain unanswered. Researchers do not yet know whether this phenomenon occurs the same way across different colorectal cancer subtypes, or whether the pattern holds in actual patients. They have not tracked nerve function in people before, during, and after chemotherapy to see if early tumor-related damage truly does make patients more vulnerable to treatment side effects. Those studies will be necessary before doctors can act on these findings.
But the implications are already clear. If tumors damage nerves before chemotherapy begins, then the chronic pain, numbness, and sensory dysfunction that plague many colorectal cancer survivors may not be entirely a side effect of their medicine. Some of that suffering may trace back to the cancer itself, to months or years of tumor-driven inflammation silently eroding the nervous system. Understanding this could reshape how doctors think about managing quality of life in survivors—and whether early detection of this hidden nerve damage might one day guide treatment decisions.
Bemerkenswerte Zitate
This nerve damage, which affects the protective insulation around nerves, is largely latent and could have major implications for quality of life in survivors, even when there are no obvious pain symptoms.— Andrew Shepherd, Ph.D., associate professor of Translational Neuroscience at UT MD Anderson
Möchten Sie die ganze Geschichte?
Das Original lesen bei News-Medical ↗
Health & Medicine